Article

Single-sample strategies for early rule-out of myocardial infarction

Published on 24 nov., 2026 | 2 min read
A nurse takes a blood sample from a seated older patient while a heart is displayed on a screen behind.

Key takeaways

  • Single-sample rule-out strategies using high-sensitivity cardiac troponin can help emergency teams identify patients at low risk of myocardial infarction earlier, supporting timely discharge decisions and potentially reducing the need for repeat testing 

  • The pathway rules out a heart attack, which can help support clinical judgement, not replace it, leaving room to investigate other causes of chest pain

  • Gen 6's improved precision at low troponin concentrations enables the evaluation of new assay-specific thresholds, with recent clinical evidence suggesting that more patients could be identified as low risk after a single test

Why rapid rule-out matters

Chest pain is one of the highest-volume presentations in emergency medicine, yet only a minority of these patients are having a heart attack. An estimated 1.4 million chest-pain attendances occur across England each year, of whom perhaps one in ten to one in fifteen receive a diagnosis of myocardial infarction (MI).1

Because the low-risk group is so large, any strategy that safely identifies dischargeable patients earlier could  scale into a substantial system-level effect. In this interview, Freddy Thurston, Clinical Research Fellow in Cardiology at the University of Edinburgh, discusses how single-sample rule-out pathways work, how they are evaluated for safety, and what a newer, higher-precision troponin assay could mean for the number of patients safely discharged on a single test.

Strategies to rule out myocardial infarction

Single-sample rule-out strategies use a high-sensitivity cardiac troponin measurement at presentation to identify patients at very low risk of myocardial infarction, when appropriate clinical criteria are met. For eligible patients, this can support earlier discharge decisions without the need for serial troponin measurements. The goal is efficacy: maximizing the proportion safely ruled out on one blood draw.

Established rapid algorithms, also called accelerated diagnostic pathways, such as European Society of Cardiology (ESC) 0/1- and 0/2-hour, also allow selected patients to be ruled out based on the initial sample alone. Other patients require serial measurements, with classification informed by absolute troponin concentrations and their changes over time. Single-sample strategies are designed to widen the group eligible for rule-out on that first measurement. Thurston notes, however, that the proportion of eligible patients actually discharged varies widely between sites.

Crucially, these are decision-support tools, not substitutes for clinical assessment. Applied where pre-test probability is negligible, they can drive over-investigation. A negative result speaks only to MI: "we know it's not myocardial infarction for now", Thurston says, stressing the need to keep a broad differential.

Rapid rule-out protocols for MI: Safety rests on 30-day outcomes

Establishing that a threshold is safe requires a conservative yardstick. Derivation studies count not only MI diagnosed at presentation but any MI or cardiac death out to 30 days, holding the algorithm accountable even for a diagnosis of MI missed at first assessment. Safety is assessed by examining the negative predictive value (NPV) and sensitivity for myocardial infarction or cardiac death at 30 days, alongside the uncertainty around these estimates. Together, these measures help determine how reliably a strategy identifies patients at very low risk. 

Gen 6: Potential to expand single-sample rule-out

Troponin T hs Gen 5 already supports single-sample rule-out in selected patients. Troponin T hs Gen 6 offers enhanced analytical precision at low troponin concentrations, enabling the evaluation of new risk-stratification thresholds based on clinical performance. Importantly, differences in assay standardization mean that Gen 5 and Gen 6 results are not directly interchangeable, and assay-specific decision thresholds are required. Because the assay measures accurately in the concentration range relevant to identifying very-low-risk patients, Thurston's research systematically assessed a range of low thresholds to find the one that identified the most low-risk patients without compromising safety.

In a recently published study involving 987 patients across three Scottish emergency departments, researchers identified a TnT hs Gen 6-specific threshold of less than 13 ng/L that achieved a negative predictive value of 99.9% and sensitivity of 99.4% for type 1, 4b or 4c myocardial infarction or cardiac death at 30 days. This assay-specific threshold was subsequently evaluated within the high-sensitivity troponin in the evaluation of patients with acute coronary syndrome (High-STEACS) early rule-out pathway.2 Applied this way, TnT hs Gen 6 identified 41.0% of patients as low risk at presentation, compared with 17.4% using Gen 5, while the proportion requiring serial troponin measurements fell to 23.2% (from 43.4%). These findings suggest the potential to reduce repeat testing, although the impact on routine clinical practice remains to be established. 

In the external advantageous predictors of acute coronary syndrome evaluation (APACE) validation cohort, the TnT hs Gen 6 High-STEACS pathway identified 30.1% of patients as low risk at presentation, with a sensitivity of 98.7% and NPV of 99.1%. Although these results support the potential of the approach across different clinical settings, performance was lower than in the derivation cohort. As Thurston notes, prospective implementation studies are still needed to confirm the effect on real-world practice.

Diagnostic accuracy of novel biomarkers for MI

Very early presenters remain a challenge for single-sample rule-out, since troponin takes hours to peak and concentrations may not yet have risen enough to reliably exclude myocardial infarction. Thurston mentions two options. The first is a second biomarker such as cardiac myosin-binding protein C, which is released faster than troponin and, in prototype-assay studies, showed stronger discrimination in early presenters, though further clinical validation is needed. The second is setting the threshold lower than the standard single-sample cut-off, which preserves sensitivity and increases the proportion dischargeable on one test at the cost of some added complexity.3

From evidence to implementation

While these findings are promising, patient management in the study was guided by existing clinical assays. Prospective implementation studies are therefore needed to confirm whether TnT hs Gen 6-based strategies can safely reduce serial testing, emergency department length of stay and hospital admissions in routine clinical practice. 

Email Icon

Join the CarDiaLogue

Join the CarDiaLogue today and sign up for updates.

Contributors

Roche Logo

Freddy Thurston

Illustration of a heard and cardiologists

Join the CarDiaLogue community

CarDiaLogue brings you the latest valuable perspectives from some of the sharpest minds in cardiology to complement your specialist skills.

We provide access to insights from world-renowned experts and thought leaders, sharing the latest clinical evidence, presenting the newest guidelines, offering educational events, and providing actionable insights for the management of cardiometabolic diseases.

Get a free copy of our latest infographic when you sign up for the CarDiaLogue community and be the first to receive updates with the latest cardiology insights.

Investigator-initiated study supported in part by a Roche Diagnostics International award; funding paid to the institution.

References

  1. Statista. Number of A&E attendances in England in 2024/25, by chief complaint. [Internet, cited 2026 November 9] Available from: https://www.statista.com/statistics/1537396/number-of-accident-and-emergency-attendances-by-chief-complaint-in-england/.

  2. Thurston AJF, et al. Early rule out of myocardial infarction with a novel high-sensitivity cardiac troponin T assay. JAMA Cardiol. 2026;11(6):583-92 

  3. Lopez-Ayala P, Boeddinghaus J, Koechlin L, et al. Incremental value of cardiac myosin-binding protein C for the early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2025;86(25):2616–32.